Related News
Home » Metro » Health and Science
Diabetes profiling link-up
By Cai Wenjun |
April 9, 2013, Tuesday
|
Online Edition
Online Edition
CHINA'S National Center for Drug Screening in Shanghai announced today a collaboration with the US-based PerkinElmer, Inc. to advance personalized medicine and drug profiling for diabetes patients in China.
Scientists will validate new diagnostics for Asian populations through utilizing next generation sequencing technologies.
Once optimized, the technology platform will be able to disseminate its knowledge to hospitals and testing laboratories throughout China.
"We will test all known biomarkers of diabetes to select special diabetes-related biomarkers in Chinese patients," said Wang Mingwei, director of the National Center for Drug Screening.
Several biomarkers have been established in Western populations as predictive markers for drug efficacy.
These are used to make decisions on treatments.
But the validation of these markers has been primarily conducted on Caucasian populations and have not yet been validated on the Chinese populations.
"We will do sequencing Chinese patient samples in order to establish genomic information for drug profiling in China," Wang said.
Currently, different Chinese diabetes patients are usually given the same medicines initially.
Some patients have to try different medicines until seeing the effects.
This is not only bad for treatment but also a waste of money and time, say experts.
Individualized medicine is the trend of modern medicine and a smart use of current medicine by the largest extent, say experts.
The United States Food and Drug Administration requires mandatory biomarker tests for 26 approved drugs and recommends biomarker tests for 90 other approved drugs.
Scientists will validate new diagnostics for Asian populations through utilizing next generation sequencing technologies.
Once optimized, the technology platform will be able to disseminate its knowledge to hospitals and testing laboratories throughout China.
"We will test all known biomarkers of diabetes to select special diabetes-related biomarkers in Chinese patients," said Wang Mingwei, director of the National Center for Drug Screening.
Several biomarkers have been established in Western populations as predictive markers for drug efficacy.
These are used to make decisions on treatments.
But the validation of these markers has been primarily conducted on Caucasian populations and have not yet been validated on the Chinese populations.
"We will do sequencing Chinese patient samples in order to establish genomic information for drug profiling in China," Wang said.
Currently, different Chinese diabetes patients are usually given the same medicines initially.
Some patients have to try different medicines until seeing the effects.
This is not only bad for treatment but also a waste of money and time, say experts.
Individualized medicine is the trend of modern medicine and a smart use of current medicine by the largest extent, say experts.
The United States Food and Drug Administration requires mandatory biomarker tests for 26 approved drugs and recommends biomarker tests for 90 other approved drugs.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
